Cargando…

Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”

Detalles Bibliográficos
Autores principales:	Nieto-Gómez, Pelayo, Castaño-Amores, Celia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630292/ https://www.ncbi.nlm.nih.gov/pubmed/37707706 http://dx.doi.org/10.1007/s40120-023-00537-x

Ejemplares similares

Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
por: Lager, Brittney, et al.
Publicado: (2023)

Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis
por: Lager, Brittney, et al.
Publicado: (2022)

Diroximel fumarate for multiple sclerosis
Publicado: (2022)

Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence
por: Liseno, Jacob, et al.
Publicado: (2021)

Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis
por: Kuchimanchi, Mita, et al.
Publicado: (2022)

Vaginal Herpes Zoster While Under Treatment for Relapsing-Remitting Multiple Sclerosis With Diroximel Fumarate
por: Gül, Sedat, et al.
Publicado: (2023)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
por: Hauer, Larissa, et al.
Publicado: (2022)

Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews
por: Gudesblatt, Mark, et al.
Publicado: (2022)

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
por: Singer, Barry A, et al.
Publicado: (2023)

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
por: Naismith, Robert T, et al.
Publicado: (2019)

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
por: Naismith, Robert T., et al.
Publicado: (2020)

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study
por: Palte, Michael J., et al.
Publicado: (2019)

Letter to Editor Regarding the OCEAN Study [Letter]
por: Yawn, Barbara P, et al.
Publicado: (2021)

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study
por: Wundes, Annette, et al.
Publicado: (2021)

Letter to the Editor Regarding Vaping Article
por: Spitz, Rabbi Yehuda
Publicado: (2019)

Letter to the Editor Regarding Esophageal Dysfunction and Systemic Sclerosis: Drugs Should be Kept in Mind
por: Bernal-Bello, David, et al.
Publicado: (2022)

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study
por: Wray, Sibyl, et al.
Publicado: (2022)

Response letter regarding the letter to the editors by Brown et al.
por: Taylor, Sylvia, et al.
Publicado: (2016)

Letter to the Editor Regarding “Surgical Management of Recurrent and Persistent Macular Holes: A Practical Approach”
por: Garcin, Thibaud
Publicado: (2022)

Letter to the editor: Regarding the editorial by Penttinen and Friede
por: Fry, Alicia M, et al.
Publicado: (2016)

Letter to the Editor Regarding “Letter to the Editor: Spinal and Neurosurgical Publications During the COVID-19 Era”
por: Akhaddar, Ali, et al.
Publicado: (2020)

Letter to the Editor
por: Gomez‐Nieto, Diego, et al.
Publicado: (2015)

Letter to the Editor: Regret after Gender-affirmation Surgery: A Systematic Review and Meta-analysis of Prevalence
por: Expósito-Campos, Pablo, et al.
Publicado: (2021)

A Response to: Letter to the Editor Regarding [Esophageal Dysfunction and Systemic Sclerosis: Drugs Should be Kept in Mind]
por: Li, Bo, et al.
Publicado: (2022)

Letter to the Editor Regarding: A Comprehensive Review on Copemyl(®)
por: Comi, Giancarlo, et al.
Publicado: (2018)

Letter to the editor regarding “Rotavirus infection beyond the gut”
por: Orrico-Sánchez, Alejandro, et al.
Publicado: (2019)

Letter to the Editor: Regarding “The Role of Obesity in Pediatric Orthopedics”
por: Rehm, Andreas, et al.
Publicado: (2020)

Letter to the editor regarding the paper “Tick infestation of the eyelid”
por: Dantas-Torres, Filipe
Publicado: (2020)

Letter to the Editor: Regarding COVID-19 in Children with Asthma
por: Özdemir, Öner
Publicado: (2021)

Letter to the editor regarding the article of Chen et al.
por: Islamoglu, Mehmet Sami, et al.
Publicado: (2022)

Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”
por: Boudier-Revéret, Mathieu, et al.
Publicado: (2022)

Letter to the editor regarding “Selfies: A boon or bane?”
por: Kazerooni, Rashid
Publicado: (2022)

Letter to the Editor Regarding: Evolving Business Models in Orthotics
por: Laakso, L.
Publicado: (2022)

Letter to the editor regarding “unusual extraneural metastasis of glioblastoma”
por: Waack, Andrew Leland, et al.
Publicado: (2023)

Letter to Editor regarding “Unusual Presentation of Spontaneous Chylothorax”
por: Varghese, Anjali Rachel, et al.
Publicado: (2022)

Reply to Letter to the Editor: Regarding “The Role of Obesity in Pediatric Orthopedics”
por: Nowicki, Philip, et al.
Publicado: (2020)

Letter to the editor regarding “disparities in telemedicine during COVID‐19”
por: De, Brian, et al.
Publicado: (2022)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mieekhl51f93phihc6bpgsdqsm